Business
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibranor Daix (France), New York City (New York, United States), October 7, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steat
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation of digital pathology data from preclinical studies with lanifibranor","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":203,"olType":false},{"type":"text","content":"Daix (France), New York City (New York, United States), October 7, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced four abstracts presentations at the upcoming Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 being held November 7 to 11, 2025 in Washington, DC.","length":533,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follow:","length":43,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:150.87px;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Abstract title","length":14,"tagName":"p","attribs":{}}]},{"style":"width:519.47px;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Comparison of digital images versus glass slides for the histopathological evaluation of liver biopsy samples according to the NASH-CRN scoring system for MASH: A validation performed as part of the NATiV3 study","length":211,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:150.87px;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Type of presentation ","length":20,"tagNam...